Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > CR at 450
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(548)
•••
Comment by Rumpl3StiltSkinon Jul 24, 2022 1:34pm
157 Views
Post# 34846395

RE:RE:RE:RE:RE:CR at 450

RE:RE:RE:RE:RE:CR at 450
CancerSlayer wrote:

 

Rumpl3StiltSkin wrote: It is also the inexact nature of the delivery system for NMIBC. Once TLT gets 1433/Rutherrin into solid tumors the PR-CR %s will be a lot higher, IMO...  

 

 

For deeper solid tumors, the greater challenge will not be with drug delivery, but will be with trying to achieve precise/optimal light or energy delivery in whatever form it's given.  The drug has been proven to perform exceedingly well in multiple cancers preclinically, including in an NSCLC cell line as demonstrated by Roswell Park.  Those TLD-1433 preclinical studies demonstrated a 100% cell kill when the proper amount of energy/fluence was administered (in this case = 20 J/cm2).  So, the drug certainly works....just need to perfect the method/delivery of light or energy.



Yes, and It would be very nice if TLT could demonstrate PDC activation using XRays... Would certainly simplify delivery for the solid tumors. Wonder when they will complete their GLP for this?


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities